Financing channel feed – Endpoints News

Financing channel feed

Denali IPO hits a 2017 record $1.7B market valuation, raising $250M for neurodegeneration R&D

8 years ago

Sexual harassment in biotech hits home as OrbiMed’s Sam Isaly steps down in wake of STAT report

8 years ago

Rich Heyman's Metacrine grabs a $22M round in search of a superior NASH drug

8 years ago

Looking for the next big breakthrough in CAR-T, Mike Gilman debuts Obsidian with $49.5M round

8 years ago

Michael Pellini has just joined Bill Maris at Section 32 — focused on patient care and drug development

8 years ago

Atox Bio closes $30M round as it speeds through late-stage trials

8 years ago

Anti-aging startup ResTORbio gets $40M to fuel Phase IIb study

8 years ago

Looking to cure Type 1 diabetes, investors front $114M to launch a pioneering human study at Semma

8 years ago

New backers Sofinnova and Scopia bring Y-mAb's round to $80M for anti-cancer drugs

8 years ago

Frazier backs MavuPharma’s $20M round, brings in heavyweight execs to lead

8 years ago

Doug Williams ups the ante at Codiak Bio to $168.5M in a drive to first human study

8 years ago

RA backs Medeor’s $57M round as researchers fast forward to PhIII

8 years ago

AstraZeneca teams with China-owned fund to launch a new biopharma drug development company

8 years ago

Six top biotech VCs take a look at the latest trends, and offer their thoughts on 2018

8 years ago

French upstart Step Pharma raises €8.6M, taking immunosuppressive drugs to the clinic

8 years ago

ScPharmaceuticals raises $90M in IPO with heart failure drug on deck

8 years ago

What's a successful failure? Atlas' Booth sounds taps for Merck-backed Quartet Medicine

8 years ago

Arsanis prices $40M IPO for infectious disease work

8 years ago

X4 raises $27M to take Sanofi’s old drug through pivotal trial

8 years ago

Johns Hopkins has $65M to spend on taking their drugs right up to human studies

8 years ago

$49M round; experienced team; A-list VCs — Inozyme launches with rare disease strategy and a yen for bigger things to come

8 years ago

Award-winning sepsis project gets $13M and a shot at reopening an R&D avenue as FDA pitches out old gold standard

8 years ago

San Diego’s stealthy Odonate surfaces with $173M IPO

8 years ago

ImmusanT scores a $40M round for PhII celiac study, with biotech vet Tom Daniel joining the board

8 years ago

First page Previous page 135 136 137138139 140 141 Next page Last page